Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent (IC) and data protection declaration~2. Female outpatients aged 18 to 70 years~3. Sum-score of the main uUTI symptoms (dysuria, pollakisuria, and urgency) reported on the Acute Cystitis Symptom Score (ACSS)-Typical domain at Visit 1 is ≥6~4. Symptoms of the acute episode of lower uUTI are developed within not more than 6 days prior to Visit 1~5. Leukocyturia at Visit 1, confirmed by positive dipstick~6. Patients willing to refrain from consuming prohibited concomitant medications and products~7. Non-lactating female patients who are surgically sterile (have had a documented sterilization, bilateral oophorectomy at least 3 months before the start of the trial and/or hysterectomy), or postmenopausal (cessation of menses for at least 12 months), or women of childbearing potential with a negative pregnancy test at Visit 1 willing to use highly effective (failure rate less than 1% per year, i.e., Pearl Index \<1) contraception methods, e.g., contraceptive patch, oral, injected or implanted hormonal methods of contraception, during the trial including the follow-up period.~Exclusion Criteria:~1. Any signs of complicated urinary tract infections (UTIs), pyelonephritis (i.e., fever T ≥38.0°C \[grade 2\], flank and/or back pain, chills and shivers), and/or vulvo-vaginitis with vaginal and/or with urethral discharge (without urination) at Visit 1.~2. Any conditions that may lead to complicated infections (i.e., renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, uncontrolled diabetes mellitus, spinal cord injury, etc.).~3. Chronic infection of the urinary tract known from medical history.~4. Persisting signs or symptoms of severe, progressive, or uncontrolled systemic disease (i.e., renal, hepatic, biliary, hematological, gastro-intestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease).~5. Uncontrolled hypertension (a diastolic blood pressure \>95 mmHg at Visit 1).~6. Known severe cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at Visit 1.~7. Any antibiotic therapy within 30 days prior to Visit 1.~8. Other acute infections (except uUTIs) requiring antibiotic treatment at Visit 1.~9. Patients receiving treatment for suspected or confirmed UTI (antibiotic or phytopharmaceutical) within 30 days prior to Visit 1.~10. Patients who took anti-inflammatory drugs (e.g., ibuprofen) or spasmolytics for any reason within 24 hours prior to Visit 1, and/or are not willing to stop the intake of any of the medication not permitted for use during the trial.~11. Known severe impaired renal function (creatinine clearance \<20 mL/min).~12. Active peptic ulcers.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group Canephron® N (Type: ACTIVE_COMPARATOR): Canephron® N \& fosfomycin trometamol-placebo
- Group Fosfomycin Trometamol (Type: ACTIVE_COMPARATOR): Canephron® N-placebo \& fosfomycin trometamol

Based on this trial design, predict the completion outcome and termination type (if applicable).